World: Game-changing HIV prevention drug must be available for $40 per year — everywhere

Doctors Without Borders/Médecins Sans Frontières (MSF) has initiated a campaign urging Gilead Sciences to enhance the global availability of lenacapavir, a long-acting injectable HIV prevention drug. Currently, Gilead restricts the supply of this essential medication to low- and middle-income countries and sells it at exorbitant prices, limiting access for those most at risk of HIV infection. MSF highlights that lenacapavir, which is nearly 100 percent effective and requires administration only twice a year, is crucial for populations such as gay men, transgender individuals, and those in humanitarian crises. The organization calls for lenacapavir to be priced at no more than $40 per year and emphasizes the need for governments to intervene to override Gilead's monopoly if necessary, to ensure equitable access to this transformative medicine.

Read More